Crinetics Pharmaceuticals (NASDAQ: CRNX) presented results from its Phase 2 trial of atumelnant for congenital adrenal hyperplasia at the Endocrine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA